MolNFT v1 · #176842 · protein
Crystal structure of upa in complex with cleaved camostat
7DZD · Urokinase-type plasminogen activator: “Crystal structure of upa in complex with cleaved camostat”. X-ray diffraction, 1 ligand (GBS), 1 pocket (best druggability 0.49). MolNFT v1 #176842 on GenesisL1: 3D structure, binding sites and…
- PDB
- 7DZD
- Type
- protein
- Length
- 245 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Urokinase-type plasminogen activator
- EC
- 3.4.21.73
- UniProt
- P00749
- Ligands
- GBS
- Pockets
- 1 · best druggability 0.49
Structure
x-ray diffraction · 1 distinct chain · 11% helix, 39% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| U | Urokinase-type plasminogen activator (EC 3.4.21.73) | protein | 245 | 11% helix, 39% strand | P00749 |
Ligands and binding sites
- GBS · 4-guanidinobenzoic acid · ligand · chains U
- PGE · Triethylene glycol · additive · 2 copies · chains U
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 197 | 0.49 | 0.76 | 35 | GBS |
Modifications
Observed in the structure: 5 disulfide, 1 covalent (disulfide, covalent ligand).
Compared structures
- 7DZD · Crystal structure of uPA in complex with cleaved camostat · the same entry in another collection · chain U against U, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P00749
- Elsewhere: RCSB PDB 7DZD · PDBe 7DZD · UniProt P00749
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.